FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4226127671> ?p ?o ?g. }

• W4226127671 endingPage "45" @default.
• W4226127671 startingPage "35" @default.
• W4226127671 abstract "It is important to evaluate whether a new treatment for heart failure with reduced ejection fraction (HFrEF) provides additive benefit to background foundational treatments. As such, we aimed to evaluate the efficacy and safety of empagliflozin in patients with HFrEF in addition to baseline treatment with specific doses and combinations of disease-modifying therapies.We performed a post-hoc analysis of the EMPEROR-Reduced randomised, double-blind, parallel-group trial, which took place in 520 centres (hospitals and medical clinics) in 20 countries in Asia, Australia, Europe, North America, and South America. Patients with New York Heart Association (NYHA) classification II-IV with an ejection fraction of 40% or less were randomly assigned (1:1) to receive the addition of either oral empagliflozin 10 mg per day or placebo to background therapy. The primary composite outcome was cardiovascular death and heart failure hospitalisation; the secondary outcome was total heart failure hospital admissions. An extended composite outcome consisted of inpatient and outpatient HFrEF events was also evaluated. Outcomes were analysed according to background use of angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs) or angiotensin receptor neprilysin inhibitors (ARNIs), as well as β blockers and mineralocorticoid receptor antagonists (MRAs) at less than 50% or 50% or more of target doses and in various combinations. This study is registered with ClinicalTrials.gov, NCT03057977.In this post-hoc analysis of 3730 patients (mean age 66·8 years [SD 11·0], 893 [23·9%] women; 1863 [49·9%] in the empagliflozin group, 1867 [50·1%] in the placebo group) assessed between March 6, 2017, and May 28, 2020, empagliflozin reduced the risk of the primary outcome (361 in 1863 participants in the empagliflozin group and 462 of 1867 in the placebo group; HR 0·75 [95% CI 0·65-0·86]) regardless of background therapy or its target doses for ACE inhibitors or ARBs at doses of less than 50% of the target dose (HR 0·85 [0·69-1·06]) and for doses of 50% or more of the target dose (HR 0·67 [0·52-0·88]; pinteraction=0·18). A similar result was seen for β blockers at doses of less than 50% of the target dose (HR 0·66 [0·54-0·80]) and for doses of 50% or more of the target dose (HR 0·81 [0·66-1·00]; pinteraction=0·15). Empagliflozin also reduced the risk of the primary outcome irrespective of background use of triple therapy with an ACE inhibitor, ARB, or ARNI plus β blocker plus MRA (given combination HR 0·73 [0·61-0·88]; not given combination HR 0·76 [0·62-0·94]; pinteraction=0·77). Similar patterns of benefit were observed for the secondary and extended composite outcomes. Empagliflozin was well tolerated and rates of hypotension, symptomatic hypotension, and hyperkalaemia were similar across all subgroups.Empagliflozin reduced serious heart failure outcomes across doses and combinations of disease-modifying therapies for HFrEF. Clinically, these data suggest that empagliflozin might be considered as a foundational therapy in patients with HFrEF regardless of their existing background therapy.Boehringer Ingelheim and Eli Lilly and Company." @default.
• W4226127671 created "2022-05-05" @default.
• W4226127671 creator A5000146546 @default.
• W4226127671 creator A5000241840 @default.
• W4226127671 creator A5000340011 @default.
• W4226127671 creator A5000528736 @default.
• W4226127671 creator A5000570214 @default.
• W4226127671 creator A5001493274 @default.
• W4226127671 creator A5001572526 @default.
• W4226127671 creator A5001669594 @default.
• W4226127671 creator A5001704230 @default.
• W4226127671 creator A5001709390 @default.
• W4226127671 creator A5002170104 @default.
• W4226127671 creator A5002215587 @default.
• W4226127671 creator A5002408583 @default.
• W4226127671 creator A5002692864 @default.
• W4226127671 creator A5002850904 @default.
• W4226127671 creator A5002881888 @default.
• W4226127671 creator A5002990536 @default.
• W4226127671 creator A5003268151 @default.
• W4226127671 creator A5003381137 @default.
• W4226127671 creator A5003409008 @default.
• W4226127671 creator A5003478654 @default.
• W4226127671 creator A5003833126 @default.
• W4226127671 creator A5003943960 @default.
• W4226127671 creator A5003947990 @default.
• W4226127671 creator A5003965883 @default.
• W4226127671 creator A5004007476 @default.
• W4226127671 creator A5004018720 @default.
• W4226127671 creator A5004045527 @default.
• W4226127671 creator A5004086646 @default.
• W4226127671 creator A5004184756 @default.
• W4226127671 creator A5004416125 @default.
• W4226127671 creator A5004750391 @default.
• W4226127671 creator A5005007989 @default.
• W4226127671 creator A5005132393 @default.
• W4226127671 creator A5005137768 @default.
• W4226127671 creator A5005161552 @default.
• W4226127671 creator A5005221349 @default.
• W4226127671 creator A5005477413 @default.
• W4226127671 creator A5005515052 @default.
• W4226127671 creator A5005631453 @default.
• W4226127671 creator A5005781762 @default.
• W4226127671 creator A5005962160 @default.
• W4226127671 creator A5005998988 @default.
• W4226127671 creator A5006065644 @default.
• W4226127671 creator A5006080229 @default.
• W4226127671 creator A5006159317 @default.
• W4226127671 creator A5006175809 @default.
• W4226127671 creator A5006223372 @default.
• W4226127671 creator A5006486818 @default.
• W4226127671 creator A5006819657 @default.
• W4226127671 creator A5006956106 @default.
• W4226127671 creator A5007108790 @default.
• W4226127671 creator A5007158205 @default.
• W4226127671 creator A5007247112 @default.
• W4226127671 creator A5007353842 @default.
• W4226127671 creator A5007422276 @default.
• W4226127671 creator A5007651781 @default.
• W4226127671 creator A5007733072 @default.
• W4226127671 creator A5007750245 @default.
• W4226127671 creator A5007820479 @default.
• W4226127671 creator A5007836212 @default.
• W4226127671 creator A5007979246 @default.
• W4226127671 creator A5008035375 @default.
• W4226127671 creator A5008177500 @default.
• W4226127671 creator A5008286721 @default.
• W4226127671 creator A5008314723 @default.
• W4226127671 creator A5008382551 @default.
• W4226127671 creator A5008473990 @default.
• W4226127671 creator A5008530481 @default.
• W4226127671 creator A5008704300 @default.
• W4226127671 creator A5009897097 @default.
• W4226127671 creator A5010237143 @default.
• W4226127671 creator A5010363799 @default.
• W4226127671 creator A5010398474 @default.
• W4226127671 creator A5010416419 @default.
• W4226127671 creator A5010545135 @default.
• W4226127671 creator A5010906391 @default.
• W4226127671 creator A5011066941 @default.
• W4226127671 creator A5011073716 @default.
• W4226127671 creator A5011117734 @default.
• W4226127671 creator A5011208442 @default.
• W4226127671 creator A5011414462 @default.
• W4226127671 creator A5011777173 @default.
• W4226127671 creator A5012373197 @default.
• W4226127671 creator A5012382878 @default.
• W4226127671 creator A5012423826 @default.
• W4226127671 creator A5012433331 @default.
• W4226127671 creator A5012464194 @default.
• W4226127671 creator A5012537545 @default.
• W4226127671 creator A5012557260 @default.
• W4226127671 creator A5012574422 @default.
• W4226127671 creator A5013000950 @default.
• W4226127671 creator A5013360298 @default.
• W4226127671 creator A5013388230 @default.
• W4226127671 creator A5013536491 @default.
• W4226127671 creator A5013720745 @default.

• next